InsidersTradesSigma
Track the Anika Therapeutics, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Anika Therapeutics, Inc. has logged 50 public disclosures. Market capitalisation: €256.8m. The latest transaction was filed on 7 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Colleran David. Every trade is accessible without an account.
50
Insider Decl.
n/a
Thresholds
€631,081
10 ops.
Buy Volume
€70,539
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Anika Therapeutics, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$21.00.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,016 of 29,064 companies
36.7
score / 100
Value36
Quality38
FCF yld1.5%
Earn yld-3.9%
EV/EBITDA·
ROE-2.2%
Gross mgn57%
Net mgn-9.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 August 2026
Declarations50 total
16,864 shares@ US$21.0659CommonSEC144:0001959173-26-005793
1,000 shares@ US$20.7450.0081% mcap50.5% of flowCommon StockSEC:0001193125-26-335269:0
Canonical exit: 1 Nov 2026 (T+90)
1,000 shares@ US$20.3150.0079% mcap49.5% of flowCommon StockSEC:0001193125-26-335269:1
Canonical exit: 2 Nov 2026 (T+90)
10,402 sharesCommon StockSEC:0001193125-26-279535:0
10,402 sharesCommon StockSEC:0001193125-26-279539:0
10,402 sharesCommon StockSEC:0001193125-26-279541:0
10,402 sharesCommon StockSEC:0001193125-26-279542:0
10,402 sharesCommon StockSEC:0001193125-26-279545:0
12,840 sharesCommon StockSEC:0001193125-26-259520:0
3,769 shares@ US$14.410.024% mcap100.0% of flowCommon StockSEC:0001193125-26-259520:1
12,200 shares@ US$12.28530.072% mcap73.2% of flowCommon StockSEC:0001193125-26-197887:0
Canonical exit: 29 Jul 2026 (T+90)
9,388 sharesCommon StockSEC:0001193125-26-111511:0
12,824 sharesCommon StockSEC:0001193125-26-111502:0
24,519 sharesCommon StockSEC:0001193125-26-111494:0
3,774 sharesCommon StockSEC:0001193125-26-111492:0
5,465 sharesCommon StockSEC:0001193125-26-102240:0
20,001 sharesCommon StockSEC:0001193125-26-102239:0
2,197 sharesCommon StockSEC:0001193125-26-102238:0
7,954 shares0Common StockSEC:0001171843-22-004301:0
7,954 shares0Common StockSEC:0001171843-22-004297:0
7,954 shares0Common StockSEC:0001171843-22-004300:0
7,954 shares0Common StockSEC:0001171843-22-004302:0
7,954 shares0Common StockSEC:0001171843-22-004299:0
7,954 shares0Common StockSEC:0001171843-22-004298:0
1,500 shares@ US$21.370.015% mcap45.5% of flowCommon StockSEC:0001171843-22-003615:0
Canonical exit: 9 Aug 2022 (T+90)
25 of 50 declarations
关于 Anika Therapeutics, Inc.
Anika Therapeutics, Inc.（股票代码：ANIK）是一家在美国纳斯达克市场上市的美国公司。对于法国、比利时和瑞士的投资者而言，Anika 最好被视为一家专注于早期骨科干预、骨关节炎疼痛管理和再生解决方案的专业医疗保健和骨科公司。该公司成立于 1992 年，总部位于马萨诸塞州贝德福德，其平台围绕透明质酸（HA）构建，透明质酸是一种天然存在的聚合物，在关节健康和组织功能中发挥作用。([sec.gov](https://www.sec.gov/Archives/edgar/data/898437/000114036126017488/ny20067128x1_def14a.htm?utm_source=openai)) Anika 的业务围绕开发、制造和商业化差异化的骨科产品展开。其主要的骨关节炎疼痛管理系列产品包括 Monovisc、Orthovisc 和 Cingal，所有这些产品都以基于 HA 的治疗方法为核心，旨在帮助缓解膝关节疼痛并改善功能。其再生解决方案产品组合包括 Integrity、Hyalofast 和 Tactoset，它们分别针对肌腱修复、软骨再生和骨修复支持。该公司还在主要市场通过合作模式运营；值得注意的是，Monovisc 和 Orthovisc 在美国通过 J&J MedTech 独家销售，而其他产品则通过国际商业合作伙伴分销。([anika.com](https://anika.com/about-anika/?utm_source=openai)) 从竞争角度来看，Anika 是一家专注的利基市场参与者，而非广泛的医疗技术综合企业。其差异化优势来自于在基于 HA 的生物材料方面的长期专业知识、集中的骨科产品组合以及针对高价值临床领域的战略。这种专业化对于寻求骨科和再生医学领域投资的投资者可能具有吸引力，但这也意味着该公司对监管时机、报销动态和商业执行的敏感度高于规模更大的多元化同行。近期报告显示出喜忧参半的背景：国际商业活动和 Integrity 植入系统表现出增长势头，而美国骨关节炎疼痛管理则面临 Monovisc 和 Orthovisc 的价格压力。([sec.gov](https://www.sec.gov/Archives/edgar/data/898437/000114036126017488/ny20067128x1_def14a.htm?utm_source=openai)) 近期里程碑事件意义重大。自 2026 年 2 月 1 日起，Cheryl Blanchard 过渡为执行主席，Steve Griffin 成为总裁兼首席执行官。2025 年，公司继续推进其产品线，包括向 FDA 提交 Hyalofast 的 PMA 申请，并继续进行与 Cingal 相关的监管工作。管理层还强调了商业渠道的增长和再生解决方案的进展，这进一步证实了 Anika 正在努力将其产品组合重新平衡到更高增长、更高利润的骨科机会。对于投资者而言，ANIK 是一家具有重要产品线选择权的专业医疗保健公司，在美国纳斯达克上市，最好通过产品执行、监管催化剂和合作伙伴主导的商业化视角进行评估。([sec.gov](https://www.sec.gov/Archives/edgar/data/898437/000114036126017488/ny20067128x1_def14a.htm?utm_source=openai))
